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Background
Human gamma-herpesviruses, Epstein-Barr virus (EBV
or HHV-4) and Kaposi’s sarcoma-associated herpesvirus
(KSHV or HHV-8), are associated with several malig-
nancies, especially in AIDS patients. Although highly
active antiretroviral therapy (HARRT) has significantly
reduced the incidence of EBV- and KSHV-associated
tumors, it does not eliminate EBV or KSHV infection,
and the tumor risk remains high for HIV-1-infected
individuals who are also carriers for EBV and KSHV.
Tumorigenesis of gamma-herpesviruses is associated
with the persistence of infection. Thus, vaccination to
elicit protective immunity that inhibits the establishment
of viral persistence will prevent the occurrence of virus-
associated cancers. However, currently there are no
effective vaccines available for KSHV or EBV.
Material and methods
For proof of concept vaccination experiments, we utilize a
mouse gamma-herpesvirus infection model. Previously, we
have shown that vaccination with a non-persistent highly
lytic live attenuated virus (AC-RTA) provides effective
protection against a challenge infection by the wild type
virus. To increase the safety of vaccination, the in vivo
lytic replication capacity of a live gamma-herpesvirus
needs to be significantly weakened without losing immu-
nogenicity. We hypothesize that removal of the viral genes
that inhibit the host immune responses will reduce the
fitness of the virus but potentially increase its immuno-
genicity. For this purpose, we have removed immune eva-
sion genes from AC-RTA along with other modifications.
Results
The resultant virus named DIP (Deficient in Immune eva-
sion and Persistence), replicates in cell culture but is
severely attenuated in mice, deficient in acute productive
infection and latency. However, immunization of the DIP
virus prevents latency establishment by the challenge wild
type virus. Next, we aim to test strategies to improve the
immunogenicity in immunocompetent and CD4-deficient
hosts by incorporating expression of co-stimulatory mole-
cules into the DIP virus.
Conclusions
The non-persistent DIP virus that undergoes limited in
vivo viral replication provides us a novel vaccine strategy
for preventing infection of human gammaherpesviruses.
The “proof of concept” study in the mouse infection
model is necessary to provide fundamental insights into
the development of vaccines for the tumor-associated
human herpesviruses.
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